Evidence map›Paper›PMID 34753434›Full record

ArticleBMC cancer2021

Correction to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.

Mustafa Erman, Bivas Biswas, Pongwut Danchaivijitr, Lingwu Chen, Yoke Fui Wong, Tarek Hashem, Chun Sen Lim, Bulent Karabulut, Hsiao-Jen Chung, Chandrasekhar Chikatapu and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Mustafa ErmanMedical Oncology, Hacettepe University, Ankara, Turkey.
Bivas BiswasMedical Oncology, Tata Medical Center, Kolkata, West Bengal, India.
Pongwut DanchaivijitrMedical Oncology, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Lingwu ChenMedical Oncology, The First Affiliated Hospital of Sun Yat-sen, Guangzhou, Guangzhou, Guangdong Province, China.
Yoke Fui WongRadiotherapy and Oncology, National Cancer Institute, Putrajaya, Malaysia.
Tarek HashemMedical Oncology, Dr. Tarek Hashem's Clinic, Cairo, Egypt.
Chun Sen LimClinical Oncology, Sultan Ismail Hospital, Johor Bahru, Malaysia.
Bulent KarabulutMedical Oncology, Ege University, Izmir, Turkey.
Hsiao-Jen ChungDepartment of Urology, Taipei Veterans General Hospital and Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Chandrasekhar ChikatapuOncology, Novartis Healthcare Pvt. Ltd., Hyderabad, Telangana, India.
Sara InglesOncology, Novartis Pharma AG, Basel, Switzerland.
Khemaies SlimaneOncology, Novartis Pharma SAS, Rueil-Malmaison, France.
Ravindran KanesvaranDivision of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. ravindran.kanesvaran@singhealth.com.sg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34753434
PMCPMC8576870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.